VANCOUVER, BC / ACCESSWIRE / March 20, 2017
Abattis Bioceuticals Corp. (ATTBF) (CSE:ATT) (the “Company” or “Abattis”) is pleased to announce that Dr. David Galvez, PhD, will be joining the team to lead Northern Vine’s Science Advisory efforts.
Dr. Galvez received his doctorate in Plant Physiology at the University of Alberta and is a seasoned expert in the formulation and commercialization of botanical-based products, with a focus on using traditional, non traditional, and functional ethnobotanical plant extracts and powders. David’s previous position was Director of Research & Development at ZAG Global, where he successfully developed and launched four commercial products in the dietary supplement market for pain relief, sleeplessness, relaxation, and anxiety management, both in capsule and 2-oz drink formats. He is widely published in highly ranking peer reviewed scientific journals and has in-depth knowledge on the proper handling and protection of intellectual property.
“We are excited to have someone of David’s caliber and industry specific experience join our team at Northern Vine, and look forward to working with him to analyze and identify superior strains, extraction methods, and formulations for our program,” stated Rene David, newly appointed board member at Abattis. “Northern Vine is strategically preparing for the future of the legal cannabis industry in Canada and the addition of Dr. Galvez further positions us, not only as a leader in cannabis testing, but also the technology and intellectual property aspects of the business.”
“The Cannabis Industry is set to become a powerful economic driver across North America and in Europe. Once economies of scale commoditize the production of raw materials, profits in the sector will be led by players offering value-added products and services. I believe Abattis is uniquely positioned to provide high quality services and finished products in a very specialized niche within the Industry,” said Dr. Galvez.
Northern Vine is scheduled to launch next month and management will continue to provide updates in the lead up to this event.
About Abattis Bioceuticals Corp.
Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company’s website at: www.abattis.com.
About Northern Vine Canada Inc.
Northern Vine Labs™ is licensed by Health Canada for the possession of Cannabis and related active ingredients, as well as the production of extracts for the purpose of analysis. Northern Vine Labs™ product certification and quality assurances programs incorporate global best practices and procedures for application in the legal Canadian Cannabis market.
ON BEHALF OF THE BOARD
Rene David, CFO, Director
For further information, contact the Company at (604) 336-0881 or at email@example.com.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements. The use of any of the words “anticipate,” “continue,” “estimate,” “expect,” “may,” “will,” “project,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE: Abattis Bioceuticals Corp.